Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,492 across all filing types
Latest filing 2025-04-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
独立董事2024年度述职报告-屈勇刚
Board/Management Information Classification · 95% confidence The document is an Independent Director's 2024 Annual Work Report for Tian Kang Biological Co., Ltd. It details the independent director's duties, attendance at board and shareholder meetings, communication with auditors, and oversight activities during the year 2024. It references compliance with laws and regulations, participation in board committees, and supervision of company governance and financial reporting. The document is a detailed report on the independent director's activities and responsibilities over the year, not an announcement or a brief summary. It is not a full annual report (10-K) or audit report (AR), but rather a management-related report focusing on governance and oversight by an independent director. This fits best under Board/Management Information (MANG), which includes announcements of changes or reports related to board members and senior management activities. The document length is under 5,000 characters but contains substantive content about the independent director's role and activities, not just an announcement of a report publication. Therefore, the classification is MANG with high confidence.
2025-04-28 Chinese
商誉减值测试报告
Annual Report Classification · 95% confidence The document is titled '2024 年年度报告商誉减值测试报告' which translates to '2024 Annual Report Goodwill Impairment Test Report'. It contains detailed financial data related to goodwill impairment testing, including asset group valuations, impairment indicators, assumptions, discount rates, and impairment loss calculations. The presence of comprehensive financial figures and analysis indicates this is a substantive financial report rather than a brief announcement or certification. The document length is 4598 characters, which is sufficient to contain detailed financial data. The content aligns with an Annual Report or a detailed financial report section within an annual report. Given the focus on goodwill impairment testing for the 2024 fiscal year, this is part of the official yearly financial reporting. Therefore, the appropriate classification is Annual Report (10-K). FY 2024
2025-04-28 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Tian Kang Biological Co., Ltd. regarding changes in accounting policies. It details the reasons for the changes, the dates of implementation, the previous and new accounting policies, and the impact on the company's financial status and results. It also includes opinions from the audit committee, board of directors, and supervisory board approving the changes. The document is relatively short (3394 characters) and serves as a formal announcement of accounting policy changes rather than a full financial report or audit report. It does not contain comprehensive financial statements or detailed audit results but focuses on policy changes and approvals. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-28 Chinese
中信建投证券股份有限公司关于天康生物股份有限公司2024年度募集资金存放与实际使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a securities company (中信建投证券股份有限公司) acting as a sponsor and continuous supervisor for 天康生物股份有限公司. It focuses on the 2024 annual special verification opinion regarding the storage and actual use of raised funds (募集资金) from a non-public stock issuance. The document includes detailed financial figures about the amount raised, usage, balance, and compliance with regulatory requirements. It also contains an auditor's opinion on the fund usage and storage, and a detailed table of fund usage. The document is 7,529 characters long, which is substantial and contains actual financial data and analysis, not just an announcement or certification. The content aligns with a specialized audit or verification report on fundraising and fund usage, which fits the category of Audit Report / Information (AR) rather than a full Annual Report (10-K) or a simple announcement. Therefore, the document is best classified as an Audit Report / Information (AR). FY 2024
2025-04-28 Chinese
年度募集资金使用鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金存放与使用情况鉴证报告" which translates to "Verification Report on the Deposit and Use of Raised Funds." It is issued by an accounting firm and includes detailed information about the company's fundraising amount, usage, management, and compliance with regulatory requirements. The document references specific regulatory guidelines related to the management and use of raised funds by listed companies in China, and it contains detailed financial data about the raised funds' deposit and usage during the fiscal year 2024. This type of report is a specialized audit or assurance report focusing on the use of capital raised by the company, rather than a full annual report or interim financial report. It is not a simple announcement or certification but a standalone audit/verification report on a specific aspect of the company's financials. Therefore, the most appropriate classification is Audit Report / Information (AR). The document length (15,000 characters) and content confirm it is a full report, not just an announcement or certification. FY 2024
2025-04-28 Chinese
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制审计报告" which translates to "Internal Control Audit Report." It includes detailed audit opinions on the effectiveness of internal controls over financial reporting as of December 31, 2024. The document is issued by a certified public accounting firm and includes an internal control self-evaluation report by the company. It discusses the responsibilities of the company and auditors, the scope and methodology of the internal control evaluation, and the conclusions that no material weaknesses were found. The document is about the audit of internal controls rather than the full annual financial report or other types of filings. It is a standalone audit report focused on internal control effectiveness, consistent with the definition of Audit Report / Information (AR). The document length (8461 characters) is sufficient to contain substantive content, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2024
2025-04-28 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.